(Alliance News) - GSK PLC on Monday said the European Commission has approved an expanded indication for its respiratory syncytial virus vaccine Arexvy, allowing use in all adults aged 18 and over. Read More
(Alliance News) - GSK wins EU approval to expand use of its RSV vaccine Arexvy to all adults over 18, while Grainger unveils plans for a 195-home West London development, and Impax Environmental Markets outlines its tender offer plan amid continued pressure from activist investor Saba. Read More
GSK PLC - London-based pharmaceuticals company - Says China's National Medical Products Administration has approved Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, or FF/UMEC/VI) in a new indication, for adults with uncontrolled asthma. This adds to the therapy's current licence for use in chronic obstructive pulmonary disease, and makes it the first and only single inhaler triple therapy approved for the maintenance treatment of both respiratory conditions in China. GSK says approval was based on its Captain study, "which showed that in patients uncontrolled on inhaled corticosteroids/long-acting beta agonist (ICS/LABA), the additional bronchodilation provided by FF/UMEC/VI demonstrated significant improvements in lung function compared with FF/VI." Says asthma is one of the most prevalent chronic respiratory diseases in China, with around 46 million adults affected and approximately half of patients experiencing uncontrolled symptoms. Read More
RTW Biotech Opportunities Ltd - Guernsey-based investor in the life sciences sector - Notes GSK PLC's announcement on Tuesday that it has agreed to acquire RAPT Therapeutics Inc. Says RAPT, a Californian biopharmaceutical company developing therapies for inflammatory and immunologic diseases, represented 0.15% of its net asset value as of December 31. The all-cash transaction values RAPT at USD2.2 billion, with shareholders to receive USD58 per share. RTW says the price represents a 65% premium to RAPT's closing price on Monday. Read More
(Alliance News) - Stock prices in London slid further on Tuesday morning for the second day, as tariff threats from the US continued to unsettle investors. Read More
(Alliance News) - GSK PLC on Tuesday announced the USD2.2 billion acquisition of RAPT Therapeutics Inc, a California-based clinical-stage biopharmaceutical company focused on novel therapies for inflammatory and immunologic diseases. Read More
(Alliance News) - The UK unemployment rate was steady while regular earnings growth slowed, GSK agrees to buy biopharmaceutical firm RAPT Therapeutics for USD2.2 billion and Informa reports "strong trading" in the fourth quarter. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More
(Alliance News) - Stock prices in London closed higher on Thursday, after a surprise drop in US jobless claims. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - Stock prices in London opened lower on Wednesday, as the FTSE 100 retreated from a record high, as oil firms BP and Shell weighed on the blue-chip index. Read More
(Alliance News) - GSK PLC on Wednesday reported positive developments with its shingles vaccine and its potential treatment for chronic hepatitis B, as it secured a presentation approval and announced positive data. Read More
(Alliance News) - Blue chips continued their strong start to the year on Tuesday with the FTSE 100 hitting a new record led by gains in retailer Next and drug stocks, GSK and AstraZeneca. Read More
(Alliance News) - GSK PLC on Tuesday said depemokimab, sold under the brand name Exdensur, has been approved by Japan's Ministry of Health, Labour and Welfare for severe asthma and chronic rhinosinusitis with nasal polyps. Read More
(Alliance News) - GSK PLC on Monday said mepolizumab, sold under the brand name Nucala, has been approved in China for use in adults with chronic obstructive pulmonary disease. Read More
(Alliance News) - Balfour Beatty sells ten UK assets for GBP87 million, Wizz Air and Ryanair report growth in passenger numbers for December, while Auction Technology Group rejects 11 takeover proposals from FitzWalter Capital. Read More
(Alliance News) - The FTSE 100 drifted lower on Wednesday in lacklustre trading ahead of the Christmas break, although a chunky disposal by BP brought some life to proceedings. Read More
(Alliance News) - Stock prices in London opened modestly lower on Wednesday, during a shortened trading session ahead of the Christmas holiday break. Read More
GSK PLC - London-based pharmaceuticals firm - Announces agreement with the US government to lower the cost of prescription medicines for American patients, including GSK's portfolio for respiratory conditions such as asthma and COPD. Says it will lower the price of certain medicines in Medicaid and "launch new products with a more balanced pricing approach", and will make most of its inhaled respiratory portfolio and other products available to patients on a direct purchasing platform with savings of up to 66%. Furthermore, it intends to further support the US supply chain for critical medicines by securing a reserve of albuterol, the active ingredient used in many inhalers to relieve the symptoms of asthma and COPD, for the US. Read More